Atrix Laboratories and Fujisawa Healthcare have submitted a new drug application to the FDA for Aczone Gel (5% dapsone topical gel), formerly called Atrisone, for the treatment of acne vulgaris.
Aczone uses Atrix's proprietary Solvent Microparticle (SMPTM) delivery system to deliver dapsone, a water-insoluble compound with anti-inflammatory and antimicrobial properties. Dapsone currently is only commercially available for other indications as an oral tablet for systemic delivery due to the compound's water insolubility. Atrix's SMP system allows localized topical delivery of this drug.
COPYRIGHT 2004 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2005 Gale Group